Literature DB >> 2728807

Insulin-like growth factor I and daily growth hormone profile in the assessment of active acromegaly.

A Barreca1, E Ciccarelli, F Minuto, P Bruzzi, G Giordano, F Camanni.   

Abstract

A poor correlation exists between growth hormone levels and the severity of disease in patients with acromegaly. It has been suggested that insulin-like growth factor I correlates better with the clinical condition thaN GH itself, but the presence of a correlation between GH and IGF-I is still a matter of debate. We therefore studied the fasting concentration of acid-extracted IGF-I and the daily GH profile (at 08.00, 12.00, 16.00, 20.00 h) in 28 acromegalic patients, both in basal condition and at different times after treatment. All patients studied before treatment exhibited a GH mean daily concentration always above 5 micrograms/l (range 5.15-1.47 micrograms/l), and IGF-I values (1.99-6.85 U/l) always above the normal range (0.38-1.90 U/l). During the follow-up after medical, surgical or radiation therapy we did not observe normalization of the IGF-I concentration for a GH day curve value above 5 micrograms/l. Compared with the GH day curve, a single morning GH value was slightly less sensitive and definitely less specific. The analysis of covariance evidenced a good correlation (P less than 0.001) between the GH day curve and IGF-I concentration during the first 6 months of medical as well as during the first year of radiation therapy, and after surgical treatment. Our data indicate that a single determination of acid-extractable IGF-I is as reliable as GH multiple sampling to assess the acromegalic disease activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2728807     DOI: 10.1530/acta.0.1200629

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  8 in total

1.  Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa.

Authors:  M Giusti; L Foppiani; P Ponzani; C M Cuttica; M R Falivene; S Valenti
Journal:  J Endocrinol Invest       Date:  1997-05       Impact factor: 4.256

2.  Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1 (IGF1) levels at birth.

Authors:  Mark P Rogan; Leah R Reznikov; Alejandro A Pezzulo; Nicholas D Gansemer; Melissa Samuel; Randall S Prather; Joseph Zabner; Douglas C Fredericks; Paul B McCray; Michael J Welsh; David A Stoltz
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

3.  Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience.

Authors:  Francesco M Minuto; Eugenia Resmini; Mara Boschetti; Alberto Rebora; Laura Fazzuoli; Marica Arvigo; Massimo Giusti; Diego Ferone
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

Review 4.  Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.

Authors:  A Giustina; A Barkan; P Chanson; A Grossman; A Hoffman; E Ghigo; F Casanueva; A Colao; S Lamberts; M Sheppard; S Melmed
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

5.  Hormonal and radiological effects of megavoltage radiotherapy in patients with growth hormone-secreting pituitary adenoma.

Authors:  E Ciccarelli; M R Valetto; E Vasario; T Avataneo; S Grottoli; F Camanni
Journal:  J Endocrinol Invest       Date:  1993-09       Impact factor: 4.256

6.  Effect of low-dosage recombinant human growth hormone therapy on pulmonary function in hypopituitary patients with adult-onset growth hormone deficiency.

Authors:  I Meineri; O Andreani; R Sanna; A Aglialoro; G Bottino; M Giusti
Journal:  J Endocrinol Invest       Date:  1998 Jul-Aug       Impact factor: 4.256

Review 7.  Serum IGF-I levels in the diagnosis and monitoring of acromegaly.

Authors:  A M Brooke; W M Drake
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

Review 8.  Defining normalcy of the somatotropic axis: an attainable goal?

Authors:  Ariel L Barkan
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.